Clinical Trial

Finerenone for Patients With Primary Aldosteronism (FAIRY)

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 30, 2024 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-08; most recent amendment 2024-08-28.
Trial Details
NCT Number NCT06457074
Lead Sponsor Qifu Li
Collaborators: The Affiliated Hospital Of Southwest Medical University, The First Affiliated Hospital of Zhengzhou University, Second Affiliated Hospital, Zhejiang University, School of Medicine, Changzhi Medical College
Conditions Primary Aldosteronism
Enrollment 306 participants
Start Date 2024-06-04
Primary Completion 2025-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-30